Chemotherapy-elicited upregulation of NKG2D and DNAM-1 ligands as a therapeutic target in multiple myeloma. - RIIP - Réseau International des Instituts Pasteur Access content directly
Journal Articles OncoImmunology Year : 2013

Chemotherapy-elicited upregulation of NKG2D and DNAM-1 ligands as a therapeutic target in multiple myeloma.

Abstract

Malignant cells constitutively express Natural killer group 2, member D (NKG2D) or DNAX Accessory Molecule-1 (DNAM-1) ligands, yet they are often unable to trigger a robust cytotoxic cell response. It may be therapeutically useful to implement strategies aimed at increasing the density of NKG2D and DNAM-1 ligands on the surface of cancer cells, endowing them with the capacity to activate potent antitumor natural killer-cell responses.

Domains

Immunology Cancer
Fichier principal
Vignette du fichier
Soriani_et_al.pdf (424.42 Ko) Télécharger le fichier
Origin : Publication funded by an institution
Loading...

Dates and versions

pasteur-01054170 , version 1 (05-08-2014)

Identifiers

Cite

Alessandra Soriani, Cinzia Fionda, Biancamaria Ricci, Maria Luisa Iannitto, Marco Cippitelli, et al.. Chemotherapy-elicited upregulation of NKG2D and DNAM-1 ligands as a therapeutic target in multiple myeloma.. OncoImmunology, 2013, 2 (12), pp.e26663. ⟨10.4161/onci.26663⟩. ⟨pasteur-01054170⟩

Collections

RIIP RIIP_FCB
25 View
110 Download

Altmetric

Share

Gmail Facebook X LinkedIn More